Navigation Links
Ventolin

ProductsVentolin
Company ARUP Laboratories
Item Ventolin
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Ventolin, Urine
TAG: Ventolin
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades.
This is a perfect tool for retrieving free floating sections from the Vibratome bath.
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray.
Vibratome Specimen Adhesive is a special formulation developed by a major adhesive manufacturer for applications such as tissue mounting. The advantage of this adhesive is that it has a strong holdi
Medicine Products:
(Date:11/21/2008)... Barr Pharmaceuticals, In...lders overwhelmingly approved the proposals submit... Teva Pharmaceuticals Industries Ltd. (Nasdaq: T...overwhelming support of the transaction by the Bar...rman and CEO. "We are pleased with the progress th...
(Date:11/21/2008)... deadly diseaseits cause remains a mysteryswept in... with citizens, soldiers and refugees of the war t...illed with corpses, social order broke down. Over ...nd Athens lost a third of its population. It lost ...ning of the end of the Golden Age of Greece. , ...
(Date:11/21/2008)... 21 A prestigious group of physici...gather in Williamsburg, VA on March 27-29, 2009 at...al information on cutting-edge therapeutic protoco...search advances that impact patient care. The full... information is available at www.bioconferences.c...
(Date:11/21/2008)...use is more prevalent and smoking cessation less l...tivity Disorder (A.D.H.D.) In a study of smokers ... those who exhibited elevated hyperactivity and im...er quit rates after 8 weeks than those with inatte... symptoms. The study, now available online in Ni...
Breaking Medicine News(10 mins):Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2
...leadership in the companion fields of stem cell re...of Wisconsin-Madison will establish a new Stem Cel...ent of the new center, to be made today (May 17) a...ental biologist Ian Wilmut, the creator of the clo...
...uffer in silence, cough up more money to get thing...lts. And here comes the news that a hospital grou...its workmanship, charging a flat fee that includes...nt. Even if a patient suffers complications or ha...
...are, Dr. David Parirenyatwa, says that the illegal...verely compromised the country's health delivery ... World Health Assembly in Geneva, Switzerland, to ...onditional lifting of these sanctions. He calls t...
... response to numerous complaints over local health...tient clinic in Evansville city that would open b...ut 87,000 square feet that must be available for o...l veterans have complained for nearly two years ab...
Other Medicine News:Health News:UW Establishes Stem Cell and Regenerative Medicine Center 2Health News:US Hospital Group Offers Warranty on Surgeries 2Health News:US Hospital Group Offers Warranty on Surgeries 3Health News:Sanctions Imposed On Zimbabwe Can Threaten International Health Security 2
(Date:11/20/2008)...mber 20 Arpida (SWX:,AR...Advisory Committee of the,U.S. Food and Drug Admi...proval of intravenous iclaprim, an antibiotic curr...s with complicated skin and skin structure infecti...in-resistant Staphylococcus,aureus (MRSA). , ...
(Date:11/20/2008)... -- Clinical data from a prospective,registry pre...m shows DVT,treatment with the Trellis(R) Periphe...Santa Clara, CA) successfully breaks up the blood ... This technique, called isolated pharmacomechani...y and safely than current catheter-directed thromb...
(Date:11/19/2008)...eve statistical significance , , ISELIN, N....poration (Nasdaq: PARS ) today announced results...anoEmulsion (NE) drug delivery technology formulat...he multi-center, randomized, double-blinded, place...acy of the Company,s 3% Diclofenac Diethanolamine ...
(Date:11/18/2008)...e-FirstCall/ -- NeuroDiscovery Ltd (ASX:,NDL), a ...evelopment Company,and Sosei Group Corporation (...rnational biopharmaceutical company, today announc...al pre-clinical efficacy data for NSL-043/SD118.,...or neuropathic pain and has,successfully complete...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Nicotine Plus Alcohol May Be Tough to Beat 5651 1Nicotine Plus Alcohol May Be Tough to Beat 5651 2Nicotine Plus Alcohol May Be Tough to Beat 5651 3AIM Quoted Verona Pharma Progresses Anti Asthma Drug Studies 1705 1AIM Quoted Verona Pharma Progresses Anti Asthma Drug Studies 1705 2Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases 771 1Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases 771 2MicroActive Corporation Acquired by Linden and Edgewater 5649 1MicroActive Corporation Acquired by Linden and Edgewater 5649 2
...CAGO--(BUSINESS WIRE)--Jun 4, 2007 - Genentech, In... a joint analysis of two Phase,III clinical trials...ant treatment of HER2-positive breast cancer. Data...can Society of Clinical,Oncology (ASCO) showed tha...e addition of Herceptin to standard adjuvant thera...
...UTH SAN FRANCISCO, Calif., June 04, 2007,/PRNewswi...d,follow-up data from a Phase 2 clinical trial of ... conducted by the Johns Hopkins,Sidney Kimmel Canc...rable pancreatic cancer who received GVAX after su...tion and,chemotherapy. , ,The median overall survi...
Other Medicine Technology:Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer 2Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer 3Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer 4Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer 5Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer 6Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 2Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 3Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 4Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 5